107 results on '"Kastelein, John J.P."'
Search Results
2. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
3. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
4. Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
5. Moving Targets: Recent Advances in Lipid-Lowering Therapies
6. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1
7. Response by Kusters et al to Letter Regarding Article, “Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)”
8. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
9. Novel lipid modifying drugs to lower LDL cholesterol
10. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief Report
11. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
12. What does the future hold for cholesteryl ester transfer protein inhibition?
13. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
14. PCSK9 Inhibitors and Cardiovascular Events
15. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
16. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives
17. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
18. Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence
19. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
20. Management of Hypercholesterolemia in Children
21. Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs
22. Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
23. Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia
24. The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
25. Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study
26. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study
27. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein
28. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care
29. Loci influencing blood pressure identified using a cardiovascular gene-centric array
30. LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?
31. Diagnosis and treatment of familial hypercholesterolaemia
32. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden
33. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants
34. Follow-Up of Children Diagnosed with Familial Hypercholesterolemia in a National Genetic Screening Program
35. De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
36. Antisense oligonucleotides for the treatment of dyslipidaemia
37. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia
38. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
39. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
40. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels
41. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
42. High Prevalence of Mutations in LCAT in Patients with Low HDL Cholesterol Levels in the Netherlands: Identification and Characterization of Eight Novel Mutations
43. Varespladib: targeting the inflammatory face of atherosclerosis
44. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients
45. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women
46. Genetic Variant of the Scavenger Receptor BI in Humans
47. Assessment of atherosclerosis: the role of flow-mediated dilatation
48. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study
49. C-reactive protein is a mediator of cardiovascular disease
50. Biological, clinical and population relevance of 95 loci for blood lipids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.